China’s national drug regulatory authority announced Monday that it has given the green light to a new stomach cancer treatment developed by CARsgen Therapeutics.
The treatment, commercially referred to as satri-cel, has made history as the world’s first CAR T-cell therapy designed to combat solid tumors to reach the new drug application stage globally, according to information published on CARsgen’s website.
CAR T-cell therapy — short for chimeric antigen receptor T-cell therapy — is a form of immunotherapy that works by taking a patient’s own immune cells and engineering them in a laboratory to recognize and attack cancer cells within the body.
